Drug Type Antibody drug conjugate (ADC) |
Synonyms YB1 ADC PDL1 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Preclinical | CN | - |